Published

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: International Journal of Innovative Technologies in Social Science
Date: 2026-01-28
Source: OpenAlex
DOI: 10.31435/ijitss.1(49).2026.4711
PubMed: Unavailable

Authors

Łukasz Deska Cezary Kosmecki Dawid Głaz Natalia Kamińska Wojciech Sołtys Magdalena Stolarczyk Maksymilian Głaz Mateusz Stronczyński Aleksandra Jagura-Sukiennik Julia Wawerska

Watch author

Derived topics and classifications

psilocybin Depression Chronic Pain Neuroplasticity Mechanism of Action Receptor Pharmacology Clinical Trial Systematic Review Review Article Treatment-Resistant Depression Safety Adverse Events Toxicity Systematic Review

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION2026-01-28

Related papers

Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimizationFrontiers in Psychiatry · 2025-04-08 Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?Clinical Pharmacology & Therapeutics · 2023-10-05 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10 A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19 Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.Trials · 2024-07-03